



1624/9

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 16th day of November, 2001.

[Signature]
(Signature of person mailing)
ROY F. WALDRON

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: J. W. Coe et al. :
SER. NO.: 09/402,010 :
FILING DATE: September 28, 1999 :
TITLE: ARYL FUSED AZAPOLYCYCLIC :
COMPOUNDS :

Examiner: B. Coleman
Group Art Unit: 1624

Commissioner for Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

RECEIVED
DEC 06 2001
TECH CENTER 1600/2900

Transmitted herewith is [X] a Response and Amendment; [X] a Petition for Extension of Time; [X] a Supplemental Information Disclosure Statement; and [X] a Form PTO-FB-A820 (2x); in the above-identified application.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2)	(3)	(4)	(5)	(6)
	Claims Remaining After Amendment		Highest Number Previously Paid For	Present Extra	Additional Fee
Total Claims	15 *	minus	20 **	= 0	X \$18.00 0
Independent Claims	2 *	minus	3 ***	= 0	X \$84.00 0

☐ Multiple Dependent Claim(s) fee \$280.00 0
TOTAL= 0

- * If the entry in column 2 is less than the entry in column 4, write "0" in column 5.
** If the "Highest No. Previously Paid for" is less than 20, write "20" in this space.
*** If the "Highest No. Previously Paid for" is less than 3, write "3" in this space.

☒ No additional fee is required.

- ☒ A **Petition for Extension of Time** for responding within one month(s) of the response date is also enclosed. The Commissioner is authorized to charge the fee pursuant to 37 C.F.R. § 1.17(a)(2) in the amount of \$ **110.00** to Pfizer Deposit Account No. 16-1445. Two copies of this paper are enclosed.
- ☒ Applicants submit herewith an **Information Disclosure Statement** pursuant to 37 C.F.R. §§ 1.97(c) and 1.98 with accompanying Form PTO-A820 (2x). This Statement is being filed more than three months after the filing date of the application and after the receipt of a First Office Action on the merits, but before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311. The Commissioner is hereby authorized to charge the requisite fee under 1.17(p) of \$ **180.00** to Deposit Account No. 16-1445, as well as any other additional fees which may be required under 37 C.F.R. §§ 1.16 and 1.17, or to credit any overpayment, to Deposit Account No. 16-1445. Two copies of this paper are enclosed.
- ☐ Please charge Deposit Account No. 16-1445 in the amount of \$ _____. Two copies of this paper are enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. §§ 1.16 and 1.17, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Date: 11/16/2001

Respectfully submitted,



Roy F. Waldron
Attorney for Applicants
Reg. No. 42,208

Pfizer, Inc
Patent Department
150 East 42nd Street (150/05/49)
New York, NY 10017-5755
(212) 733-5086